The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is highly competitive. This is attributed to the rise in demand for safe and effective NASH therapeutics and diagnostics, as a result, market players are focusing on launching novel products in the market.
Some of the key players in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market are Novartis AG, Allergan Plc., Viking Therapeutics, Merck & Co., Zydus Cadila, Novo Nordisk A/S, GENFIT SA, Gilead Sciences Inc., Galmed Pharmaceuticals, Madrigal Pharmaceuticals, and Intercept Pharmaceuticals Inc., among others.
Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients